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Abstract
Background: The treatment of endometrial cancer (EC), the most common gynecological cancer, is currently
hampered by the toxicity of current cytotoxic agents, meaning novel therapeutic approaches are urgently required.
Methods: A cohort of 161 patients was evaluated for the expression of the receptor for advanced glycation end
products (RAGE) in endometrial tissues. The present study also incorporates a variety of in vitro methodologies
within multiple cell lines to evaluate RAGE expression and antibody-drug conjugate efficacy, internalisation and
intercellular trafficking. Additionally, we undertook in vivo bio-distribution and toxicity evaluation to determine the
suitability of our chosen therapeutic approach, together with efficacy studies in a mouse xenograft model of
disease.
Results: We have identified an association between over-expression of the receptor for advanced glycation end
products (RAGE) and EC (H-score = Healthy: 0.46, SD 0.26; Type I EC: 2.67, SD 1.39; Type II EC: 2.20, SD 1.34; ANOVA,
p < 0.0001). Furthermore, increased expression was negatively correlated with patient survival (Spearman’s Rank
Order Correlation: ρ = − 0.3914, p < 0.05). To exploit this association, we developed novel RAGE-targeting antibody
drug conjugates (ADC) and demonstrated the efficacy of this approach. RAGE-targeting ADCs were up to 100-fold
more efficacious in EC cells compared to non-malignant cells and up to 200-fold more cytotoxic than drug
treatment alone. Additionally, RAGE-targeting ADCs were not toxic in an in vivo pre-clinical mouse model, and
significantly reduced tumour growth in a xenograft mouse model of disease.
Conclusions: These data, together with important design considerations implied by the present study, suggest
RAGE-ADCs could be translated to novel therapeutics for EC patients.
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One sentence summary
The Receptor for Advanced Glycation End products is dif-
ferentially expressed in endometrial cancers and druggable
via an antibody drug conjugate therapeutic approach.
Background
Gynecological cancers, encompassing cancers of the
endometrium, uterus, ovaries, cervix, vulva and vagina,
cause significant morbidity and mortality. By 2020, esti-
mates suggest there will be 892,000 new cases of
gynecological cancer annually, worldwide, leading to
499,000 deaths [1]. Treatment is complicated by the
nonspecific and highly-toxic nature of current anti-
cancer drugs, such as DNA alkylating agents or
platinum-based drugs used to treat this diseases, necessi-
tating suboptimal dosing to reduce toxicity in normal
cells and risking the emergence of drug-resistance in
cancer cells.
Endometrial cancer (EC), is the most frequently occur-
ring gynecological cancer in developed countries with
over 319,000 cases diagnosed worldwide, and in excess
of 76,000 deaths annually [2]. Morphological classifica-
tion of EC into estrogen dependent (Type I) and estro-
gen independent cancers (Type II) reflects fundamental
differences in the causes of each sub-type [2–4]. Type I
EC (80–90% of EC) is primarily due to unopposed estro-
genic stimulation (obesity, Polycystic Ovary Syndrome,
tamoxifen), and other risk factors such as early menar-
che, late menopause or nulliparity [3, 5]. Type II EC
(10–20% of EC) occurs mostly in older, multiparous
women of normal weight [3].
Despite increasing molecular knowledge of the tumori-
genesis of EC, the primary treatment option for type I
and type II EC is still surgery to remove the tumor [6].
Indications for radiotherapry are limited, and even then
only considered in an adjuvant setting. In advanced stage
type I disease and type II EC, adjuvant chemotherapy
can be advantageous [7], but many women with ad-
vanced, metastatic EC are elderly and may have under-
gone radiation therapy meaning they are especially
susceptible to the adverse effects of aggressive cytotoxic
regimens [8]. In addition, type II EC tumors typically do
not respond to hormone therapies due to a lack of ER
and PR expression [9], meaning that type II EC is associ-
ated with a high mortality rate [2, 6].
Molecular approaches to disease classification have led
to the development of targeted therapies. These therap-
ies, which can be broadly classified into angiogenesis
inhibitors, tyrosine kinase inhibitors, PI3K/Akt/mTOR
signaling modulators, human epidermal growth factor
receptor (HER) antibodies, folate antagonists and den-
dritic cell immunotherapies, remain experimental for EC
treatment and are typically reserved for patients for
whom surgery has not been successful [2, 6]. There is
therefore an urgent, unmet need for treatments that re-
duce the toxicities associated with current therapeutic
approaches, improve patient outcome and reduce the re-
liance on surgical solutions to EC treatment.
In attempting to address the limitations of existing ther-
apies, antibody-drug conjugates (ADCs) have emerged as
a promising therapeutic approach that combines the se-
lectivity of a targeted treatment with the cytotoxic potency
of chemotherapy agents. The first ADC gemtuzumab oco-
gamicin (Mylotarg®) gained clinical approval in 2000 [10],
paving the way for three further ADCs, brentuximab
vedotin (Adectris®), ado-trastuzumab emtansine (Kadcyla®)
and Inotuzumab ozogamicin (Besponsa®), which were li-
censed for the treatment of Hodgkin’s and anaplastic
large-cell lymphomas, HER-2 positive breast cancer and
relapsed or refractory B-cell precursor acute lymphoblastic
leukemia, respectively [11–13].
An essential facet of ADC development is the selection
of an appropriate target molecule that is specifically over
expressed within cancerous tissue compared to normal
tissue. Previous work within our laboratory has identi-
fied an association between the Receptor for Advanced
Glycation End products (RAGE), a multi-ligand signaling
system that drives innate immune inflammatory re-
sponses via NF-kB mediated gene activation, and
gynecological disease [14]. Non-essential to life, RAGE
expression in healthy tissue is absent or very low [15].
The only exception to this is the lungs, which express
higher levels of unique RAGE isoforms not found else-
where. Indeed, non-lung cells express RAGE mRNA that
is up to three times the length of mRNA expressed in
the lung and furthermore, the majority of cell lines stud-
ied, lack isoforms present in the lung [16]. Studies on
the function of RAGE in murine knockout models and
humans, suggest a homeostatic role in innate immunity,
specifically related to the regulation of sepsis [15, 17].
Interestingly, ligand binding to RAGE does not facilitate
clearance or degradation, but rather leads to a sustained
period of receptor-mediated activation and RAGE over-
expression. Over-expression and prolonged proinflam-
matory signaling are therefore associated with a number
of diseases including Alzheimer’s, viral infections and
the progression of several cancers [15, 18–20].
With the aim of developing a novel RAGE-targeting
ADC, we describe in vitro and in vivo characterization
with the goal of identifying lead candidates for pre-
clinical development. Immunohistochemistry confirmed
the over expression of RAGE in EC patients and thus
the suitability of RAGE as a target molecule. Novel anti-
bodies targeting different regions of the RAGE protein
were characterized in vitro. Monoclonal selection based
on antibody-peptide affinity, full characterization of
antibody-antigen kinetics using Surface Plasmon Reson-
ance, internalization dynamics, in vitro toxicity in cancer
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cell lines and in vivo bio-distribution and toxicology
identified antibodies targeting the V-region of RAGE as
suitable candidates for pre-clinical development. Our
studies also confirm that RAGE-targeting ADCs are se-
lectively toxic to RAGE expressing tumour cells in vitro,
non-toxic to normal tissue/organs in vivo, and effectively
reduce tumor growth in vivo.
Materials and methods
Detailed methodologies relating to cell culture, antibody-
drug conjugation, epitope mapping, surface plasmon
resonance and gene and protein expression analysis are
available as Additional file 1: supplemental methods. All
cell lines were obtained from The European Collection of
Authenticated Cell Cultures (ECACC, Public Health
England, UK) between 2013 & 2015 and verified
mycoplasma-free using the MycoAlert™ mycoplasma de-
tection kit (Lonza, Castleford, UK). All experiments in-
volving cell lines were conducted between passages 5 and
10 following thawing.
Patient samples
Endometrial biopsies from 161 patients (70 control, 54
type I EC and 37 type II EC) were obtained from patients
attending general gynecology clinics or postmenopausal
bleeding (PMB) clinics within the Swansea Bay and Cwm
Taf Morgannwg University Health Boards (SBUHB and
CTMUHB). Postmenopausal patients that presented with
bleeding or abnormally thickened endometrium (over 4
mm), identified incidentally in imaging investigations (ab-
dominal ultrasound, MRI) performed for other clinical rea-
sons, were included in the study. All patients with PMB or
thickened endometrium underwent transvaginal ultrasound
and Pipelle endometrial biopsy and hysteroscopy. Patients
with cancer diagnosis at Pipelle biopsy underwent staging
MRI and were scheduled for hysterectomy and/or bilateral
salpingoophorectomy for type I disease, and hysterectomy,
bilateral salpingoophorectomy, omentectomy and pelvic
node dissection for type II disease. The control group
included postmenopausal patients that underwent hysterec-
tomy for vaginal prolapse and PMB patients with normal
Pipelle sample and hysteroscopy findings.
Histological evaluation of endometrial samples, cancer
diagnosis and staging was confirmed by the pathology
department in SBUHB as part of routine clinical care.
For endometrial cancer type I tumors included grade 1
and grade 2 endometrioid adenocarcinoma. Endometrial
cancer type II included serous, clear cell and mixed
adenocarcinoma tumors and high-grade endometrioid
tumors (grade 3).
Follow-up time was up to 60 months. Survival was de-
fined as the date from confirmed histological diagnosis
after primary surgery to the date of death. Disease-free
time was defined as the date from confirmed histological
diagnosis after primary surgery to the date of recurrence
or last visit (for those in the study for less than 60
months).
Patients that were peri or premenopausal, presenting
with abnormal uterine bleeding (menorrhagia, intermen-
strual bleed, postcoital bleed, amenorrhea) were excluded
from this study. Patients with infection, chronic inflamma-
tion, autoimmune disease, endometritis, endometrial
hyperplasia, and other cancers were excluded from the
study. Ethical approval for immunohistochemistry analysis
of FFPE EC patient samples within the study was obtained
through Local Research Ethics Committee (reference 07/
WMW02/50) for the collection of biopsies from con-
sented EC patients (prospective analysis). Formal written
consent was obtained from all patients at the time of re-
cruitment into the study. Patients in control and study
groups were matched with regard to body mass index and
smoking status.
Data on age, BMI, parity, smoking status, menopausal
status, hormone intake of any type, and comorbities were
recorded in the study database. Data were also recorded
on surgical procedure, histological type and stage, adju-
vant treatment (radiotherapy, chemotherapy), follow up,
recurrence free period, post-recurrence treatment and
overall survival period.
Antibody production
Monoclonal antibodies against RAGE were produced
using standard protocols for monoclonal antibody produc-
tion [21]. Briefly, mice were immunized with keyhole
limpet hemocyanin (KLH)-conjugated RAGE, or KLH-
conjugated peptides corresponding to amino acids (aa)
198–217 or 327–344 of the RAGE protein. Clones were
selected based on a positive ELISA screen using bovine
serum albumin (BSA)-conjugated peptides. Post-fusion,
individual clones were selected by limiting dilution and
clonal expansion to identify genetically stable, antibody
producing cells for subsequent antibody production. One
clone with affinity for the full RAGE protein (RBGO1),
two clones with affinity for aa198–217 (RBGO2 and
RBGO3) and one with affinity for aa327–344 (RBGO4)
were selected for antibody production. Antibodies were
purified from tissue culture medium using protein G affin-
ity purification.
Experimental design
RAGE expression in endometrial cancer and hyperplasia.
Endometrial biopsies were obtained from patients with a
confirmed diagnosis of endometrial cancer (Type I, n =
54; Type II, n = 37), or endometrial cancer-free patients
(control, n = 70). Preparation of formalin-fixed paraffin-
embedded samples, nuclei staining, and immunohisto-
chemistry was performed as previously described using a
Ventana machine (Ventana Biotek Solutions, Tucson,
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AZ, USA) [22]. Positive (tonsil) and negative (endomet-
rial tissue lacking antibody) control sections were used
for reference. For immunohistochemistry, the anti-
human RAGE antibody (RBGO1) was used. Slides were
evaluated using a scoring system where slides are inde-
pendently read by three observers (LM, NT, DG) on a
multi headed microscope. The observers were blinded to
the patients’ diagnosis, and demographics. The intensity
of staining was scored from (0)-absent to (4)-strong. The
distribution of staining was assessed as follows: (0)-ab-
sent, (1) - less than 30%, (2)-30 to 60%, (3)-more than
60% and (4)-100% of the tissue surface stained. The data
was not normally distributed, the scoring results for the
combined data of all the samples was analyzed using the
Kruskal Wallace test followed by the Mann Whitney
test.
RAGE expression in endometrial cancer cell lines
Endometrial cancer or normal endometrial cells were
seeded (1 × 105 cells/ml) in 6-well tissue culture plates
(TPP, Trasadingan, Switzerland) in 2ml of stripped
medium, which comprised phenol red-free DMEM/F12
supplemented with 10% 2 x charcoal stripped FBS, 100
units/ml penicillin and 100 μg/ml streptomycin. Cells were
cultured for 72 h in a humidified, 5% CO2 in air atmos-
phere at 37 °C. For RAGE mRNA analysis, supernatants
were discarded and cells stored in RLT buffer (Qiagen) at
− 80 °C prior to mRNA analysis by quantitative (q) PCR.
For RAGE protein analysis, supernatants were discarded
and cells stored in RIPA buffer at − 80 °C prior to total cell
protein analysis by western blot.
Internalization of anti-RAGE antibodies
Endometrial cancer or non-malignant, primary endo-
metrial stromal cells (ESC) were seeded (1 × 105 cells/
ml) in 8-well chamber slides (BD Biosciences, Oxford,
UK) in 200 μl of stripped medium and cultured for 24 h
in a humidified, 5% CO2 in air atmosphere incubator at
37 °C. After culture, cells were washed in pre-warmed
(37 °C) Dulbecco’s phosphate buffered saline (DPBS) and
slides placed on ice. Cells were treated with control
medium or medium containing one of the α-RAGE anti-
bodies at 10 μg/ml, and the 8-well chamber slides were
incubated on ice for 30 min. Slides were then transferred
to the incubator at 37 °C for 15, 30, 60, 120 or 240 min,
before washing in DPBS and then fixing in 4% parafor-
maldehyde at 4 °C for 20 min. Where appropriate, cells
were permeabilized following fixation, by incubation in
0.01% triton X-100 in DPBS at 4 °C for 10 min. Conjuga-
tion to the pHAb Amine Reactive Dye was done accord-
ing to the manufacturer’s instructions (Promega, UK,
Cat. No. G983). Cells were then washed and stained with
goat anti-mouse IgG-Alexafluor488 diluted 1:1000 in
DPBS before nucleus staining with DAPI. Images were
acquired on a Zeiss LSM 710 confocal microscope (Carl
Zeiss Microscopy, Jena, Germany), and analyzed using
the Zen 2012 (blue edition) image analysis software (Carl
Zeiss).
RAGE-ADC in vitro efficacy screening
For 2D screening: Endometrial cancer or non-
malignant, primary ESC were seeded (5 × 102 cells/ml)
in 96-well tissue culture plates (TPP) in 100 μl of
stripped medium and cultured for 24 h in a humidified,
5% CO2 in air atmosphere incubator at 37 °C. After
culture, cells were treated with control medium or
medium containing ADCs (0.01–100 μg/ml), α-RAGE
antibody (0.01–100 μg/ml), vcE (0.01–100 μM) or mcF
(0.01–100 μM), for 96 h. Positive controls were cells
treated with 0.01% Triton X-100 in stripped medium for
the last 4 h of the experiment. Cell growth was monitored
over the 96 h period using the RealTime-Glo™ MT Cell
Viability Assay (Promega, Southampton, UK) in accord-
ance with the manufacturer’s instructions. Fluorescence
was measured at 24 h intervals using a FLUOstar Omega
microplate reader (BMG Labtech, Aylesbury, UK).
For 3D screening: Endometrial cancer cells were seeded
(1 × 103 cells/well) in a 96-well black ULA plate in 100 μl
of stripped medium and cultured for 24 h in a humidi-
fied, 5% CO2 in air atmosphere incubator at 37 °C. After
culture, cells were treated with control medium or
medium containing RBGO1 ADC (0.01–100 μg/ml),
RBGO1 antibody or mcF for 72 h. Cell viability was
evaluated after 72 h using the CellTiter 3D Glo Viability
Assay (Promega, Southampton, UK) in accordance with
the manufacturer’s instructions. Luminescence was mea-
sured using a FLUOstar Omega microplate reader (BMG
Labtech, Aylesbury, UK).
RAGE-ADC in vivo toxicity
In vivo toxicity studies were undertaken at Axis BioSer-
vices. All procedures were performed in accordance with
the Animals (Scientific Procedures) Act 1986, and the
guidance issued in ‘Responsibility in the case of Animals
in Bioscience research: expectations of the major research
council and charitable funding bodies.’
Nude athymic mice, aged 5–7 weeks and weighing
approximately 28-35 g, were divided into three treatment
groups of six mice each. Mice were treated with PBS
(control) or RBGO1 ADC at either 3 mg/kg or 20 mg/kg
via intravenous injection. Bodyweight was measured at
days 3, 6, 8, 13, 17 and 21 and mouse health assessed
daily. Half of the mice in each group were sacrificed at
24 h and the remaining half 3 wks following dosing.
After sacrifice, full blood counts were performed and
serum aspartate aminotransferase (AST) activity assessed
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by ELISA, in accordance with the manufacturer’s
instructions. Organs: brain, heart, lungs, stomach,
pancreas, liver, kidneys, ovaries, uterus, bowel and
spleen, were removed following sacrifice. Preparation of
formalin-fixed paraffin-embedded samples was per-
formed as previously described using a Ventana machine
(Ventana Biotek Solutions, Tucson, AZ, USA) [22].
HEC1A xenograft in vivo tumor reduction
All procedures were performed in accordance with the
Animals (Scientific Procedures) Act 1986, and the guid-
ance issued in ‘Responsibility in the case of Animals in
Bioscience research: expectations of the major research
council and charitable funding bodies.’
Briefly, 6 week-old female athymic nude mice were
subcutaneously inoculated with 5 × 105 HEC1A cells.
Mice bearing 5 mm in diameter tumours were distrib-
uted into three groups of 5 mice each. Mice were treated
with control (PBS), RBGO1 ADC (3 mg/kg) or mcF
(45 μg/kg, which is equivalent to the drug dose delivered
by the ADC) via intravenous injection. Treatments were
performed twice weekly for 4 weeks and tumour vol-
umes were measured twice weekly. Tumours and organs:
brain, heart, lungs, stomach, pancreas, liver, kidneys,
ovaries, uterus, bowel and spleen, were removed follow-
ing sacrifice. Preparation of formalin-fixed paraffin-
embedded samples was performed as previously
described using a Ventana machine (Ventana Biotek
Solutions, Tucson, AZ, USA) [22].
Statistical analyses
Statistical analyses were performed using IBM SPSS
Statistics 22 with biological replicate as the experimental
unit. Initially the data were tested for homogeneity, and
log or square root transformed if appropriate. Parametric
data were analyzed by analysis of variance (ANOVA)
using Dunnett’s pairwise multiple comparison t-test for
individual group comparisons. Non-parametric data
were analyzed by Kruskal-Wallis followed by Mann
Whitney U tests for multiple comparisons. Associations
were analyzed using Factorial Logistic Regression.
Overall survival and disease-free period was analyzed
using Kaplan-Meier survival analysis and where appro-
priate, curves compared using the Log Rank (Mantel-
Cox) test. Correlation within the patient data was
determined using Spearman’s Rank Order Correlation.
Co-localisation within the internalization experiments
was determined using Pearson’s correlation coefficient
(PCC) and Manders co-localisation coefficient. Data are
presented as mean with standard deviation (SD), p < 0.05
was considered statistically significant, and the number
of independent experiments is stated in the figure
legends.
Results
The receptor for advanced glycation end products is over
expressed in endometrial cancers and associated with
reduced survival
Endometrial biopsies from 161 patients (70 control, 54
type I EC and 37 type II EC) were obtained as described in
Methods (Patient demographics are shown in Additional
file 2: Table S1). Median age at presentation was 57.5 ±
10.3, 67 ± 14.8, or 72 ± 6.0 years, respectively. Mean body
mass index (BMI) at presentation was 31.1 ± 7.1, 35.6 ±
11.6, or 31.0 ± 6.2, respectively. Within the patient cohort
age was a significant determining factor for EC (Factorial
Logistic Regression = Type I EC: LR χ2 = 9.836, p = 0.003;
Type II EC: LR χ2 = 25.229, p < 0.001), but BMI, smoking,
parity and diabetes were not.
RAGE expression was apparent in the stromal cells of
the endometrium and was also detected in glandular/lu-
minal epithelium. Expression within control endometrium
was limited (Fig. 1a), whilst within endometrial biopsies
from type I (Fig. 1b) or type II (Fig. 1c) EC, significant
RAGE expression was observed. Semi-quantitative analysis
(H-score) of RAGE expression in each of the patient
groups showed a significant increase in RAGE expression
in type I and type II EC compared to control patients
(Fig. 1d; p < 0.001). RAGE expression was also signif-
ncantly greater in the type II EC patient group compared
to the type I EC group (Fig. 1d; p < 0.05). Additionally,
quantification of RAGE mRNA in patient biopsies using
quantitative (q) PCR, confirmed that RAGE mRNA ex-
pression was also significantly upregulated in type I and
type II EC compared to control patients (Fig. 1e; p <
0.001). Kaplan-Meier overall survival analysis over a 5 y
period, using number of months of survival following sur-
gery, indicated a significantly reduced survival for type II
EC compared to control patients (Fig. 1f: Log Rank (Man-
tel-Cox) test; p < 0.0001). Furthermore, correlation ana-
lysis showed a significant correlation between increased
RAGE expression and reduced survival in the type II EC
group (Spearman’s Rank Order Correlation: ρ = − 0.3914,
p < 0.05, Additional file 3: Figure S1A). Disease recurrence
following initial treatment was also common within the
type II EC group (60% by 29months; Fig. 1g). Correlation
analysis again showed a significant correlation between in-
creased RAGE expression and a reduced disease-free
period (Spearman’s Rank Order Correlation: ρ = − 0.4915,
p < 0.01, Additional file 3: Figure S1B). No correlations be-
tween RAGE expression and patient age, BMI, smoking,
parity or diabetes were apparent in any of the patient
groups.
Anti-RAGE antibodies - therapeutic approach and in vivo
biodistribution
The association between RAGE and EC led us to con-
sider anti-RAGE antibodies as a potential therapeutic
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approach. To this end, we examined RAGE expression
within four EC cell lines (Ishikawa - type I EC; and
HEC1A, HEC1B, HEC50 - type II EC) by western blot,
confocal microscopy and qPCR. In agreement with pa-
tient biopsies, high expression of RAGE was apparent in
all four cell lines but absent in primary, non-malignant
endometrial cells (Additional file 4: Figure S2A). Quanti-
fication of RAGE mRNA revealed the same pattern of
expression, with significantly (p < 0.05) more RAGE
mRNA present in EC cell lines compared to non-
malignant primary endometrial cells (Additional file 4:
Figure S2C). Immunofloursecence analysis revealed
RAGE localizes at the cell membrane (Additional file 4:
Figure S2B), and that the expression of RAGE in type II
EC cell lines is higher than the type I EC cell line tested
(Additional file 4: Figure S2D & E). Furthermore, we
evaluated the expression of RAGE in a variety of human
tissues (Brain, breast, kidney, liver, lung, lymph node,
pancreas, spleen and uterus, Additional file 5: Figure S3).
Western blot analysis confirmed that RAGE expression
was absent or very low in these healthy tissues as previ-
ously reported [15]. The only exception to this was the
lung tissue, which is known to express higher levels of
unique RAGE isoforms not found elsewhere [16].
Fig. 1 The receptor for advanced glycation end products (RAGE) is over expressed in endometrial cancer (EC) and associated with reduced
survival. RAGE expression was determined by immunohistochemistry in biopsies (n = 67) from healthy patients (a; n = 25) and patients with type I
(b; n = 24) or type II (c; n = 18) EC. Biopsies were formalin fixed and paraffin embedded before sectioning and staining with α-RAGE antibody.
Representative images were acquired on a Zeiss Axio Imager 2 microscope and analyzed using the ZEN 2012 image analysis software. Scale bars
are 50 μm. RAGE expression (H-score) was conducted blind by three of the authors (NT, LM & DG) independently and the mean score for each
slide used (d). Kaplan-Meier survival curves were constructed using Graph Pad PRISM 6 based on survival (months) following surgery (e). Within
type II EC patients, time to disease recurrence following surgery (months) was monitored (f) and correlated with RAGE expression (g).
Biodistribution studies were perfomed in nude athymic mice, which were dosed intravenously with anti-RAGE antibody conjugated to the
fluorophore Alexa-750 (3 mg/kg) and sacrificed after either 24 h or 3 wks. Organs were harvested and homogenized and the fluorescence from
the tissue slurry measured using a fluorescence microplate reader (Varioskan LUX, ThermoFisher) at wavelength 750 nM. Fluorescence was
normalised using the weight of the tissue and values expressed as Fluorescence Intensity per gram of tissue (h & i). Data points for RAGE
expression (H-score) represent individual patients (d). Data were analyzed by ANOVA and Dunnett’s pairwise multiple comparison test; values
differ from healthy, ***p < 0.001, *p < 0.05
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Next we considered the efficacy of anti-RAGE anti-
bodies as an EC therapeutic by exploring the ability of
commercially available anti-RAGE antibodies to effect
cell killing in vitro. The EC cell lines Ishikawa, HEC1A,
HEC1B and HEC50 were exposed to the following anti-
RAGE antibodies (1 μg/ml to 100 μg/ml) for periods up
to 96 h: N-16 (Santa Cruz Biotechnology, Cat. No sc-
8230), A-9 (Santa Cruz Biotechnlogy, Cat. No. sc-365,
154), ab37647 (Abcam, Cat. No. ab37647), MAB 5328
(Merck-Millipore, Cat. No. MAB5328), ab3611 (Abcam,
Cat. No. ab3611) and MAB11451 (Bio-techne, Cat. No.
MAB11451). None of the anti-RAGE antibodies tested
had any effect on cell health (Data not shown).
The abcence of in vitro cell killing with anti-RAGE
antibody alone led us to explore ADCs targeting RAGE
as a potentially more effective therapeutic strategy.
Using a small panel of antibodies (RBGO1–4) previ-
ously developed and characterized within our labora-
tory [23], we explored the suitability of ADCs as a
therapeutic approach to the treatment of EC. Initially,
we conducted in vivo bio-distribution experiments to
demonstrate the feasibility of such an approach (Fig. 1).
Anti-RAGE antibody raised against the whole RAGE
protein (RBGO1), conjugated to the fluorophore Alexa-
750 (3 mg/kg), was administered intravenously to
female athymic nude mice and mice were sacrificed
after either 24 h or 3 wks. Organs were harvested and
homogenized with the fluorescence from the tissue
slurry measured using a fluorescence microplate reader
(Varioskan LUX, ThermoFisher) at wavelength 750 nM.
Fluorescence was normalised using the weight of the
tissue and values expressed as Fluorescence Intensity
per gram of tissue. After 24 h, accumulation of anti-
RAGE antibody was apparent primarily in the uterus,
ovary and liver. Lower concentrations of antibody were
noted in the spleen, lung and kidney and concentra-
tions within other organs were at the limit of detection
(Fig. 1h & i). After 3 wks, antibody concentrations
within all organs, with the exception of the liver, were
at base levels (Fig. 1h).
As previously described, antibodies within the panel
were raised against the whole RAGE protein (RBGO1);
the C1 domain peptide, aa198–217 (RBGO2 and
RBGO3) and the transmembrane proximal region,
aa327–344 (RBGO4) [23]. To identify the binding region
of the RBGO1 antibody that was raised against the
whole RAGE protein, we conducted epitope mapping
using a peptide array of 404, 15aa peptides with a 14aa
overlap. Arrays were probed with RBGO1 antibody at 1,
10 or 100 μg/ml for 16 h at 4 °C and spot intensities
imaged using a LI-COR Odyssey imaging system. Ana-
lysis of the spot intensities indicated that the RBGO1
antibody bound with high affinity to a highly conserved
region within the V-domain of the RAGE protein.
Anti-RAGE antibodies with high binding affinity for rRAGE
are rapidly internalized following receptor binding and
trafficked to the endosomal compartment
Key to the development of an efficacious ADC is the
internalization of antibody to facilitate cytotoxin delivery
to the cell interior. Initial experiments assessed the
internalization of our panel of antibodies in HEC1A
cancer cells, which have high RAGE expression, follow-
ing incubation with 1 μg/ml of each antibody over a 1 h
period, using confocal microscopy (Fig. 2). Following
fixing and permeabilization, staining with secondary
antibody alone caused no non-specific binding or back-
ground fluorescence (Fig. 2f). HEC1A cells treated with
the RBGO4 antibody (Fig. 2e) had the lowest fluores-
cence after 1 h, with approximately 2.5-fold more fluor-
escence in cells treated with RBGO2 (Fig. 2c) or RBGO3
(Fig. 2d) antibody, and approximately 7.5-fold more in
cells treated with the RBGO1 antibody (Fig. 2b). Quanti-
fication of the mean fluorescence as a function of cell
area, showed that the quantity of fluorescence in cells
treated with the RBGO1 antibody was significantly more
(p < 0.001; Fig. 2g) than for the other 3 antibodies. Al-
though this pattern of internalisation matched our previ-
ous cell surface staining data [23], we evaluated antibody
binding kinetics to whole RAGE protein via surface plas-
mon resonance (Fig. 2h). These data confirmed that, as
previously, binding affinity between RBGO1 and RAGE
was high, whilst binding to the other three antibodies
was poor, thereby confirming that binding kinetics pro-
file of this batch of antibodies was as previously de-
scribed [23].
To confirm that the increased fluorescence observed
was due to internalization and explore the mechanism of
internalization, the RBGO1 antibody was conjugated to
a pH sensitive dye, which fluoresces under low pH con-
ditions (pH 6 to pH 4) [24]. As the pH found in endo-
somes and lysosomes falls within this range, tracking of
the anti-RAGE antibody to these organelles is therefore
possible once internalisation begins. Internalisation was
measured in all four EC cell lines following incubation
with the RBGO1-pH dye conjugate for 30 min, 1 h or 4 h
(Fig. 3). Fluoresence imaging in all four EC cell lines
(Fig. 3a) revealed the presence of internalized antibody
as early as 30 min, followed by a significant increase in
internalization up to 4 h. Quantification of this image
data using the imageJ JavaScript confirmed the signifi-
cant increase in internalized antibody over time (Fig. 3b).
Additionally, these data indicate that conjugation of the
anti-RAGE antibody does not impair internalization and
thus its suitability for ADC development.
Next we performed co-localisation experiments within
the HEC1A EC cell line to assess lysomal transport and
the accumulation of anti-RAGE antibodies following
internalization (Fig. 4). Lysosomal action was first
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inhibited by incubation of the cells with 100 nM leupep-
tin for 1 h to prevent antibody degradation within the
lysosome. Cells were then treated with anti-RAGE anti-
body conjugated to FITC (50 μg/ml) for 6 or 10 h. After
fixing and permeablisation, cells were stained with a
rabbit anti-LAMP1 antibody to detect the lysosomal
compartment. Co-localisation of the RAGE and LAMP1
was apparent following 6 or 10 h of antibody exposure
(Fig. 4a). The quantitative evaluation of co-localisation is
required to confirm fluorophore overlap is not random.
We therefore undertook Pearson’s correlation coefficient
(PCC) and Manders col-localisation coefficient to assess
co-localisation [25, 26]. Both methods confirmed the co-
localisation of anti-RAGE and anti-LAMP1 antibodies,
with up to 69% of internalized antibody located within
the lysosomal compartment (Fig. 4b).
Development and characterization of novel antibody-
drug conjugates
To further explore the utility of a RAGE targeted ADC,
we conjugated each of the four antibodies to the antimi-
totic agents: monomethyl auristatin E (MMAE), via a
lysosomally cleavable dipeptide valine-citrulline (vc)
linker; or monomethyl auristatin F (MMAF), via a non-
cleavable maleimido caproyl (mc) linker (Additional file 6:
Figure S4).
Drug loading of the conjugates was analyzed using a
combination of hydrophobic interaction chromatography
(HIC) and reverse phase chromatography - Polymer
Laboratories Reverse Phase PLRP (Additional file 7:
Figure S5). Due to the complex disulfide structure of an
IgG2b antibody and potential conjugation site variability,
the PLRP chromatographic patterns for the RBGO1
Fig. 2 RBGO1 antibody, targeting the V-region of RAGE is internalized more rapidly than antibodies targeting other regions of the RAGE protein
and binds with higher affinity to whole RAGE protein. Schematic diagram of the relative binding positions on the RAGE protein of each of the 4
antibodies tested (a). HEC1A endometrial cancer cells were treated with control medium or medium containing monoclonal antibodies against
RAGE at 37 °C for 1 h. After incubation, the cells were washed, fixed and permeabilized. Internalized antibody: RBGO1 (b), RBGO2 (c), RBGO3 (d) or
RBGO4 (e), was imaged via fluorescently labelled secondary antibodies and nuclei stained with DAPI. Cells were also incubated only with the
secondary antibody as negative control (f). Images were acquired on a Zeiss LSM 710 confocal microscope and analyzed using the Zen 2012
image analysis software. The quantity of internalized antibody was determined using Image J software as a function of cell area (g). For antibody
binding kinetics (h), antibodies were captured to a Sensor Chip CM5 via an amine coupled anti-mouse antibody followed by single-cycle kinetics
experiments. RBGO1, RBGO2, RBGO3 or RBGO4 antibodies were exposed to whole RAGE protein (2.5 to 200 nM) and data were fitted using a
one-to-one Langmuir binding model. Data are expressed as mean (SD) from 3 independent experiments. Data were analyzed by ANOVA and
Dunnett’s multiple comparison test. RBGO1 differs from each of the other antibodies, ***p < 0.001.
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antibody (Additional file 7: Figure S5A, B) were too
complex to accurately determine the average drug-
antibody ratio (DAR). They did however indicate a good
level of drug conjugation and analysis of the traces (Area
Under Curve) suggested an average DAR of 3.5. For the
RBGO2 (Additional file 7: Figure S5C, D), RBGO3 (Add-
itional file 7: Figure S5E, F) and RBGO4 (Additional file 7:
Figure S5G, H) antibodies, which were IgG1, the PLRP
traces for both vcE and mcF were clearly discernible,
showing drug loading up to a DAR of 4.
Anti-RAGE ADCs preferentially kill endometrial cancer
cells
We next compared cytotoxicity following the exposure
of normal endometrial, HEC1A or Ishikawa cancer cells
to antibodies, auristatins or ADCs (Fig. 5a–f). Cells were
cultured in the presence of vcE (Fig. 5a–c; 0.01 to
100 μM), mcF (Fig. 5d–f; 0.01 to 100 μM), RBGO1
(Fig. 5a–f; 0.01 to 100 μg/ml), RBGO1-vcE (Fig. 5a–c;
0.01 to 100 μg/ml) or RBGO1-mcF (Fig. 5d–f; 0.01 to
100 μg/ml) for 96 h and cell viability determined using
the RealTime-Glo™ MT Cell Viability Assay. Normal
endometrial cells were resistant to killing by any of the
treatments, with the lethal dose 50 (LD50) concentra-
tions for all treatments being > 100 μM (Fig. 5a, d). LD50
values for HEC1A cells (Fig. 5b, e) were: vcE = 65 μM,
mcF and RBGO1 > 100 μM, RBGO1-vcE = 13 μg/ml (≡
to 0.3 μM vcE) and RBGO1-mcF = 5 μg/ml (≡ 0.09 μM
mcF). LD50 values for Ishikawa cells (Fig. 5c, f) were:
vcE = 4 μM, mcF = 3 μM, RBGO1 > 100 μM, RBGO1-
vcE = 11 μg/ml (≡ to 0.2 μM vcE) and RBGO1-mcF =
7 μg/ml (≡ 0.1 μM mcF). These data suggested that
RBGO1-ADCs preferentially kill endometrial cancer cells
compared to normal endometrial cells. Additionally, in
Ishikawa cells, we observed a 20-fold increase in
sensitivity to killing for RBGO1-vcE compared to vcE
Fig. 3 Conjugated RBGO1 antibody is rapidly internalized and trafficked to the endomsomal compartment. HEC1A, Ishikawa, HEC50 or HEC1B
endometrial cancer cells were treated with control medium or medium containing RBGO1 antibody conjugated to a pH sensitive dye for 30 min,
1 h or 4 h (a). Images were acquired on a Zeiss LSM 710 confocal microscope and analyzed using the Zen 2012 image analysis software. The
quantity of internalized antibody was determined using Image J software as a function of cell area (G). Histogram data are expressed as mean
(SD) from 3 independent experiments (b). Data were analyzed by ANOVA and Dunnett’s multiple comparison test. Values differ from 30min,
**p < 0.01, ***p < 0.001, ****p < 0.0001
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(LD50: 4→ 0.2 μM; Fig. 5l, c); and a 30-fold increase in
sensitivity to killing for RBGO1-mcF compared to mcF
(LD50: 3→ 0.1 μM; Fig. 4o, f). In HEC1A cells, we ob-
served a more than 200-fold increase in cell sensitivity
to killing for RBGO1-vcE compared to vcE (LD50: 66→
0.3 μM; Fig. 4k, b), which could be due to higher RAGE
expression in HEC1A cells compared to Ishikawa cells.
The similarity of the LD50 values between HEC1A and
Ishikawa cells, led us to continue cytotoxicity testing in
HEC1A cells only. We evaluated the cytotoxicity of
RBGO2, RBGO3 and RBGO4 antibodies (0.01 to 100 μg/
ml), and their respective ADCs (0.01 to 100 μg/ml) in
normal endometrial and HEC1A cancer cells (Additional
file 8: Figure S6. LD50 values were > 100 μM within
normal endometrial cells for RBGO2 (Additional file 8:
Figure S6A-C), RBGO3 (Additional file 8: Figure S6G-I)
or RBGO4 (Additional file 8: Figure S6M-O) antibodies
or ADCs. Within HEC1A cancer cells (Additional file 8:
Figure S6D-F; RBGO2, J-L; RBGO3, P-R; RBGO4), LD50
values for RBGO2, RBGO2-mcF, RBGO3, RBGO3-mcF
and RBGO4 were also > 100 μM. LD50 values for
RBGO2-vcE, RBGO3-vcE, RBGO4-vcE and RBGO4-mcF
were 95 μg/ml (≡ to 2 μM vcE), 70 μg/ml (≡ to 1.5 μM
vcE), 116 μg/ml (≡ to 2.4 μM vcE) and 104 μg/ml (≡ to
2.2 μM mcF), respectively. These data suggested that
ADCs comprising RBGO2, RBGO3 or RBGO4 anti-
bodies were less efficacious than the RBGO1-ADC,
which was at least 5- (RBGO2-vcE vs RBGO1vcE) to 24-
fold (RBGO4-mcF vs RBGO1-mcF) more effective at
killing HEC1A cancer cells.
Fig. 4 Conjugated RBGO1 antibody co-localises with LAMP1 indicating lysosomal trafficking and accumulation following internalization. Following
inhibition of lysosomal action, HEC1A endometrial cancer cells were incubated with control medium or medium containing RBGO1 antibody
conjugated to FITC (50 μg/ml) for 6 or 10 h. After fixing and permeablisation, cells were stained with a rabbit anti-LAMP1 antibody to detect the
lysosomal compartment. Images were acquired on a Zeiss LSM 710 confocal microscope and analyzed using the Zen 2012 image analysis
software (a). The quantity of internalized antibody was determined using Image J software as a function of cell area (G). Histogram data are
expressed as mean (SD) from 3 independent experiments (b). Data were analyzed by ANOVA and Dunnett’s multiple comparison test. Pearson’s
correlation coefficient (PCC) and Manders col-localisation coefficient were performed to assess co-localisation. Values differ from 6 h, *p < 0.05
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Finally, to confirm that the RBGO1-ADC was specific
for RAGE, we performed blocking experminents using a
commercially available goat anti-human RAGE antibody
(N-16, Santa Cruz Biotechnology, Cat. No sc-8230) and
an anti-mouse Alexa 488 secondary, which would only
bind to the RBGO1 antibody (Additional file 9: Figure
S7). Ishikawa cells, prepared as previously described for
the internalisation experiments, were fixed and stained
for RAGE expression using the RBGO1 antibody, which
produced the same pattern of RAGE staining seen previ-
ously (Additional file 9: Figure S7A). In contrast, pre-
incubation of the cells for 1 h with the N16 antibody,
followed by staining with the RBGO1 antibody showed
no staining of the cells (Additional file 8: Figure S6B).
These data confirm the specificity of the RBGO1 anti-
body for RAGE.
RBGO1 ADC is more effective than a HER2 ADC at killing
EC cells
Having determined the greater efficacy of the RBGO1
ADC compared to the other RAGE targeting ADCs. We
evaluated the effectiveness of the RBGO1 ADC against a
vcE conjugated ADC targeting the human epidermal
growth factor receptor 2 (HER2), since this antigen is
already used as a therapeutic target for the ADC,
Kadcyla® (Fig. 5g–j). Peptide growth factors frequently
implicated in EC include members of the type I receptor
tyrosine kinase family, which includes HER2 [27]. Since
over expression of HER2 is typically associated with type
II EC [28, 29], we used HEC1A cells for our ADC com-
parison experiments because they are derived from a
type II EC tumor and express high levels of HER2 [30].
Cells were cultured in the presence of RBGO1 ADC
Fig. 5 a–f RBGO1 ADCs preferentially target endometrial cancer cells and increase drug sensitivity by up to 200-fold. Normal endometrial, HEC1A
cancer or Ishikawa cancer cells were incubated with control medium or medium containing vcE (a–c; 0.01 to 100 μM) or mcF (d–f; 0.01 to
100 μM), or RBGO1 (a–f), RBGO1 -vcE (a–c) or RBGO1 -mcF (d–f; 0.01 to 100 μg/ml) for 96 h. Cell viability was determined by RealTime-Glo™ MT
Cell Viability Assay and lethal dose 50 (LD50) values determined following curve fitting using a 4-parameter logistic model. Drug equivalencies
were calculated based on an average DAR of 3. Data are expressed as mean (SD) from 4 independent experiments and normalized to the
untreated control to account for cell growth during the period of the experiment. (g–j) RBGO1 ADC is more efficacious in HEC1A EC cells than
HER2 ADC. HEC1A EC cells were treated with RBGO1 ADC (g; 0.1 to 5 μg/ml), HER2 ADC (h; 0.1 to 5 μg/ml), or RBGO1 ADC and HER2 ADC (i; 0.1
to 5 μg/ml) for 96 h and cell viability determined at 0, 24, 48, 72 and 96 h using the RealTime-Glo™ MT Cell Viability Assay. Heat map color
intensities were based on percent cell viability compared to the untreated control (g–i; see scale in figure). Relative cell viability plots were fitted
using a 4-parameter logistic model (j). Data displayed are means of three independent experiments. Data were analyzed by ANOVA and
Dunnett’s multiple comparison test. ADCs differs from each other within the same dose, *p < 0.05, **p < 0.01
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(Fig. 5g; 0.1 to 5 μg/ml), HER2 ADC (Fig. 5h; 0.1 to
5 μg/ml), or RBGO1 ADC and HER2 ADC (Fig. 5i; 0.1
to 5 μg/ml) for 96 h and cell viability determined at 0,
24, 48, 72 and 96 h using the RealTime-Glo™ MT Cell
Viability Assay. The effectiveness of the RBGO1 ADC
(Fig. 5g) in HEC1A cells was confirmed, with dosage and
time-responses observed. A dose and time effect was
also apparent for the HER2 ADC (Fig. 5h), although far
less HEC1A cell killing was observed compared to the
RBGO1 ADC. A combination therapy approach (Fig. 5i)
demonstrated that after 96 h treatment with both ADCs,
the contribution to HEC1A cell killing of HER2 ADC
was minimal compared to the effect of RBGO1 ADC.
This was further confirmed by statistical analysis of each
of the doses tested at the 96 h time point (Fig. 5j), which
demonstrated significantly more HEC1A cell killing by
RBGO1 ADC compared to HER2 ADC (p < 0.05).
RBGO1 ADC is not toxic in a murine in vivo model
To verify the suitability of RBGO1 ADC for full in vivo
evaluation, we administered (intravenously) RBGO1
ADC (at 3 mg/kg or 20 mg/kg) to female, athymic mice.
Bodyweight was measured at days 3, 6, 8, 13, 17 and 21
and mice were sacrificed at either 24 h or 3 wks follow-
ing dosing, after which full blood counts and an aspar-
tate aminotransferase (AST) ELISA were performed.
Although bodyweight in animals treated with the high
dose of RBGO1 ADC decreased slightly during the
study, no significant changes were apparent (Fig. 6a).
Full blood counts (Additional file 10: Table S2) indicated
that animals treated with RBGO1 ADC (3 mg/kg) had a
reduced white blood cell count compared to control ani-
mals. Animals treated with RBGO1 ADC (20 mg/kg) had
reduced white blood cells and reticulocytes, and an in-
creased platelet count compared to control animals.
Serum AST activity was not elevated in any of the treat-
ment groups 24 h after dosing and only in the RBGO1
ADC (20mg/kg) treatment group 3 wks after dosing
(Fig. 6b). However, no signs of distress or ill health were
noted during the study in any of the treatment groups,
indicating that any toxicity caused by the RBGO1 ADC
was minimal even in the high dose treatment group.
Furthermore, histological analysis (Fig. 6jc) demon-
strated an absence of toxicity across all the treatment
groups. A low level of inflammation was noted in the
liver, lungs and kidneys of some animals, but as this was
observed in all treatment groups including the control it
was not a consequence of treatment with RAGE-ADC
(Additional file 11: Table S3). Cross-reactivity of the
RBGO1 antibody with murine RAGE was confirmed by
western blot analysis using the RBGO1 antibody (Fig.
6d). RAGE expression was absent in brain, kidney,
spleen, bladder, bowel, stomach, uterus, ovary and heart,
with weak expression in the liver and high expression in
the lungs noted.
RBGO1 ADC reduces tumor volume in a murine xenograft
model
To evaluate the efficacy of RBGO1 ADC in vivo we first
explored the utility of the ADC within a 3D culture
model (Fig. 7a, b). HEC1A cells were cultured in low
adherent culture plates to enable the formation of spher-
oids. Once formed, spheroids were treated with RBGO1
ADC (0.01–100 μg/ml), RBGO1 antibody (100 μg/ml) or
mcF (200 nM) for 72 h. After treatment, cell viability was
evaluated using the CellTiter 3D Glo Viability Assay. As
with the 2D culture cell killing experiments, treatment
with RBGO1 antibody had no observable effect on cell
viability, whilst treatment with mcF was effective. The
LD50 for RBGO1 ADC was 7.4 μg/ml, which was similar
to that noted within the 2D culture experiments and
confirmed the potential for the RBGO1 ADC to be ef-
fective in vivo.
In vivo efficacy was evaluated by administering
RBGO1 ADC (3mg/kg) or mcF (45 μg/kg) intravenously
to female athymic, nude mice bearing 5 mm HEC1A
xenograft tumours on a twice weekly basis for 4 weeks.
Bodyweights and tumour volumes were measured twice
weekly. After 4 weeks, mice were sacrificed and organs
harvested for evaluation of any systemic toxicity.
In keeping with the single dose toxicity studies, no
toxicity was observed in any organs for either treatment
(data not shown). No significant changes in bodyweight
were apparent (Fig. 7c). Treatment with RBGO1 ADC or
mcF, however, significantly reduced the rate of tumour
growth compared to the PBS control (Fig. 7d, p < 0.05)
suggesting the suitability of the RBGO1 ADC as a poten-
tial therapeutic approach.
Discussion
An increasing incidence of gynecological cancer [1],
together with continuing problems with toxic side-effects
of current cytotoxic therapies, mean new strategies are
needed to address the treatment challenges posed by
varying chemotherapy responsiveness and chemotherapy-
resistant populations [31]. This study explored the target-
ing of a novel biomarker of EC, RAGE, with ADCs to
determine the suitability of this therapeutic strategy for
EC.
Differential RAGE expression between non-malignant
and malignant endometrial cells was observed in patient
biopsies and the cell lines used within this study. Ele-
vated RAGE mRNA and intensive RAGE staining was
evident in biopsies from patients with type I or type II
EC, whilst expression in healthy patients was minimal.
RAGE was also clearly discernible by western blot, con-
focal microscopy and PCR in EC cell lines, but absent in
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non-malignant primary endometrial cells from patients
and all major tissues. Additionally, increased RAGE
expression was correlated with a reduced disease-free
survival time in patients with type I or type II EC, con-
firming an association between RAGE and EC. In this
context, several clinical studies have described a strong
association between RAGE expression and the aggres-
siveness of various cancer types [32]. Indeed, the clear
association between cancer and RAGE expression and
function, is well documented with reports demonstrating
RAGE expression associated with breast cancer, gastric
cancer, colon cancer, hepatocellular carcinoma,
pancreatic cancer, prostate cancer, ovarian cancer and
lung cancer, among others [33–39]. It is also noteworthy
that RAGE expression is only reduced in lung cancer,
suggesting RAGE may act as a tumour suppressor in this
organ [32]. Data obtained from murine cancer models
supports a mechanistic role for RAGE activation whereby
induction of cell signaling proteins such as AKT proteins,
the anti-apoptotic protein, BCL2, and cyclin D1, promote
tumor cell proliferation. Additionally, RAGE activation
limits apoptosis by inhibiting translocation of pro-
apoptotic p53 to the mitochondria and enhancing tumor
cell mitochondrial complex I activity and ATP production,
Fig. 6 RBGO1 ADC is not toxic in a murine in vivo model. PBS (Control) or RBGO1 ADC was administered (intravenously) to female, athymic mice
aged 5–7 weeks and weighing approximately 28-35 g, at a dose of either 3 mg/kg or 20mg/kg. Bodyweight a was measured at days 3, 6, 8, 13,
17 and 21 and mice were sacrificed at either 24 h or 3 wks following dosing, after which full blood counts and an aspartate aminotransferase
(AST) ELISA were performed (b). Organs were harvested immediately following sacrifice, and formalin fixed and paraffin embedded before
sectioning and staining with hematoxylin and eosin (c). Western blot analysis of mouse tissue was performed using the RBGO1 antibody (d).
Representative images were acquired on a Zeiss Axio Imager 2 microscope and analyzed using the ZEN 2012 image analysis software and
magnifications are shown on each image. Low level inflammatory cell infiltration is indicated in the ‘Liver’ image ( ). Data displayed in
histograms are means of three animals. Data were analyzed by ANOVA and Dunnett’s multiple comparison test. ADC treatments differ from
control, **p < 0.01
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thereby changing the bioenergetics of the cells to support
tumor growth [19, 32, 40, 41].
Within our data, high RAGE expression in EC was
correlated with a poor disease-free, or overall survival
time, and expression in type II EC was higher than in
type I EC suggesting an association with tumor aggres-
siveness in our patient cohort.
RAGE also provides a link between inflammation and
cancer development. By inducing and sustaining a pool
of transcriptionally active NF-κB proteins, RAGE signal-
ing maintains an inflammatory environment that drives
cancer progression. Thus, RAGE seems an appropriate
target for the development of novel therapies for treating
epithelial malignancies, including EC. Indeed, anti-
RAGE antibodies have previously been evaluated in
murine models for the treatment of acute sepsis (XT-
M4, a monoclonal antibody recognizing the V-domain
of RAGE) [42]; halting endotoxemia-related organ disor-
ders (abRAGE recognizing an epitope within the RAGE
extracellular domains) [43]; the inhibition of peritoneal
fibrosis in diabetic animals (anti-RAGE monoclonal
antibody recognizing the RAGE extracellular domains)
[44]; and the inhibition of tumor growth in a xenograph
melanoma model (anti-RAGE polyclonal antibody recog-
nizing the C1-domain of RAGE) [45].
Differential RAGE expression between non-malignant
and malignant endometrial cells was sufficient to afford
protection in vitro against RAGE targeting ADCs within
non-malignant cells. At the highest dose of ADC investi-
gated (100 μg/ml), the maximum killing achieved in
non-malignant cells was 30%, whilst equivalent cell kill-
ing in EC cells was achieved at 1 μg/ml of ADC, mean-
ing RAGE targeting ADCs were up to 100-fold more
efficacious in EC cells compared to non-malignant cells.
In EC cells cultured in 2D or 3D (spheroids), treatment
with antibodies alone had no cytotoxic effect and treat-
ment with auristatins alone had limited efficacy. In con-
trast, ADCs were up to 200-fold more efficacious than
treatment with auristatin alone. Additionally, we com-
pared the RBGO1 ADC to a comparable vcE-conjugated
HER2 ADC, since this antigen is used as a therapeutic
target for the ADC, Kadcyla®, HER2 is associated with
Fig. 7 RBGO1 ADC is effective within a 3D in vitro tumour model and effectively reduces tumour growth in a murine xenograft model of disease.
a, b HEC1A cells cultured in low-adherent plates to enable spheroid formation, were incunbated with medium containing RBGO1 ADC (0.01–
100 μg/ml), RBGO1 antibody (100 μg/ml) or mcF (200 nM) for 72 h. Cell viability was determined using the CellTiter 3D Glo Viability Assay and
luminescence measured using a FLUOstar Omega microplate reader. Representative images of spheroids were acquired on a Zeiss Axio Imager 2
microscope. Relative cell viability plots were fitted using a 4-parameter logistic model (J). Data displayed are means of three independent
experiments. c, d RBGO1 ADC (3 mg/kg), mcF (45 μg/kg) or PBS (Control) were adminstered intravenously to female athymic, nude mice bearing
5 mm HEC1A xenograft tumours on a twice weekly basis for 4 weeks. Bodyweights and tumour volumes were measured twice weekly. After 4
weeks, mice were sacrificed and organs harvested for evaluation of any systemic toxicity. Data displayed in are means of five animals with error
bars omitted for clarity. Data were analyzed by ANOVA and Dunnett’s multiple comparison test. Treatments differ from control (PBS), *p < 0.05
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EC, and is overexpressed in HEC1A cells [27–30, 46].
Importantly, the RAGE targeting RBGO1 ADC was
more efficacious than the similar ADC targeting HER2.
These data imply that the use of RAGE targeting ADCs
as a therapeutic strategy is highly efficacious.
Key to the development of ADCs is the optimization
of each constituent part [47]. We noted significant
variability in the internalization of each of the four anti-
bodies tested, which was associated with varying cyto-
toxic efficacy in EC cells. Several possible explanations
for this variability presented themselves, including the
location of antibody binding to RAGE protein. The main
structural and functional unit for ligand binding is
formed from the V- and C1 (VC1) regions of the RAGE
protein, and the vast majority of RAGE ligands bind to
this unit [48, 49]. Whilst a small number of RAGE
ligands, such as S100A6 and lysophosphatidic acid, bind
with low-affinity binding to the C2-domain [50, 51],
even these bind with much greater affinity to the V-
domain [52]. The VC1 region also drives the self-
association of membrane-bound RAGE molecules in the
absence of ligand [48], which is required for activation
and downstream signaling [52]. It is therefore plausible
that antibody binding location could influence receptor
activation and internalization. Internalization is a well-
known mechanism to shut down signaling of an active
receptor/ligand complex [52]. Indeed, the rapid internal-
ization of RAGE/S100 protein complexes into granular
structures has been shown [53]. RAGE receptor activa-
tion following antibody binding, might therefore be an
essential consideration when designing RAGE-targeting
ADCs.
The V-region binding antibody, RBGO1, bound to
rRAGE with greater affinity than the other antibodies
tested and was associated with rapid internalization,
tracking to the lysosomal compartment and greater cyto-
toxicity in vitro, implying the importance of this aspect
of ADC design for RAGE targeting and indeed, poten-
tially when targeting other membrane receptors for can-
cer therapy.
Preferential ligand binding through the VC1-domain
occurs because the positive charge of this domain en-
ables recognition of negatively charged ligands, even
when the electrostatic signal is weak [54]. Under physio-
logical conditions (pH 7) antibodies also carry an overall
negative charge providing a rationale for the improved
binding of the RBGO1 antibody and other antibodies
targeting the V-domain, such as XT-M4 [42]. Addition-
ally, the oligomerization driven by the VC1-domain pro-
duces clusters of RAGE molecules on the cell surface
that bind ligands more strongly than single molecules of
RAGE, and are important for sustained signaling [55].
By comparison, HER2 receptor clustering promotes the
internalization of anti-HER2 antibodies [56]. Therefore,
it is not surprising that rapid internalization of RAGE
antibodies was observed in high RAGE expressing EC
cells used in this study.
Since the bio-distribution studies had demonstrated a
wide dissemination of anti-RAGE where some accumu-
lation was observed in the liver, uterus, ovary and spleen,
it was important to demonstrate the absence of any tox-
icity within the host. Initial evaluation of the toxicity of
RAGE ADC in vivo indicted no significant toxicity asso-
ciated with the any of the doses used. It is noteworthy
that the high dose used (20 mg/kg) is three times higher
than the high dose (7 mg/kg) typically used to determine
maximum tolerated doses for ADCs clinically [57], indi-
cating that RBGO1 ADC is likely to be well tolerated.
This is of particular significance given that RAGE is also
expressed in the adult lung, which might lead to concern
regarding the safe use of a RAGE-ADC. However, Gefter
and colleagues have recently illustrated that lung iso-
forms possess distinct epitopes which are not found else-
where. They suggest that those RAGE isoforms unique
to the lung may exhibit both structural and functional
differences [16]. However, it is currently unclear as to
the specific mechanisms which give rise to any lung-
restricted isoforms. When the toxicity of RBGO1-ADC
was tested in vivo, no on-target toxicities were observed
in the lung of the treated animals. This suggests that ei-
ther RBGO1-ADC may not target membrane bound
RAGE isoforms expressed in pulmonary tissues or that
sRAGE expressed by alveolar type I epithelial cells acts
as a decoy kidnapping the drug and hence exerting a
protective effect. Therefore, it is possible that these sol-
uble variants of RAGE block the RAGE-ADCs avoiding
damage to healthy tissues.
Finally, evaluation of the efficacy of RBGO1-ADC
within a murine xenograft model demonstrated a signifi-
cant reduction in tumour growth rate compared to con-
trol animals. Whilst a similar reduction in growth rate
was also observed within animals treated with mcF
alone, the advantage of using a targeted therapeutic ap-
proach to avoid systemic toxicity associated with the use
of chemotherapeutics such as the auristatins is well
documented.
Conclusions
In summary, we show that RAGE is a suitable target for
the development of anti-cancer therapeutics. Addition-
ally, its differential expression between EC and non-
malignant cells would make it a suitable target for the
development of companion diagnostics. Our data imply
the suitability of an ADC approach as they also highlight
the importance of native protein binding affinity when
designing antibodies for this purpose and suggest a role
for receptor activation in effective ADC design. In
particular, we demonstrate the efficacy of our RAGE
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targeting ADC based on the V-region binding, RBGO1
ADC, which was up to 200-fold more efficacious than
treatment with cytotoxic drug alone. Initial toxicity
evaluation suggests a likely low toxicity and local deliv-
ery of RAGE-ADCs to the endometrium could render
this targeted therapy safe enough to be quickly directed
towards the clinic. In addition, through the murine
xenograft model, we demonstrate that RBGO1 ADC ef-
fectively reduces tumour growth and is therefore a suit-
able candidate for further pre-clinical and potential
clinical development. Future work will continue the pre-
clinical development of ADCs based on the RBGO1 anti-
body, together with efforts to elucidate important design
characteristics of ADCs that might have applicability for
multiple targets. Such findings could be translated to
novel therapeutics for endometrial cancer patients, pro-
viding rational strategies for targeting chemotherapeutic
drugs to cells expressing RAGE receptors.
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